Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
First and only anti-CD20 monoclonal antibody proven to deliver renal response benefits in a Phase III trial Twice-yearly dosing and a 90-minute infusion time Offers new hope to the 1.7 million people worldwidemostly women of colour and childbearing age affected by lupus nephritis #Roche #FDAApproval #LupusNephritis #Intellectt #Biopharma #MedicalInnovation #MonoclonalAntibody #DrugDevelopment #ClinicalTrials #Gazyva #HealthcareInnovation #LifeSciences To view or add a comment, sign in 4,026 followers
In cell line models, which display limited heterogeneity, it is less likely that clonal populations would be evident at short timepoints
What may surprise you is that some vitamins, minerals, and herbal supplements should be avoided as well
The Regents of the University of Michigan.
US$ 28.43
US$ 25.74
US$ 21.73
US$ 24.02
US$ 21.85
US$ 29.04
US$ 21.69
